Contract notice: Pharmaceutical products Tender, Germany - 14996484

Procurement Summary

Country : Germany

Summary : Contract notice: Pharmaceutical products

Deadline : 05 Jul 2019

Other Information

Notice Type : Tender

TOT Ref.No.: 14996484

Document Ref. No. : 278564-2017

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : DAK-GESUNDHEIT
Office Name: DAK-Gesundheit
Address: Nagelsweg 27-31
Town: Hamburg
Postal Code: 20097


Phone: +49 402396-2682
Fax: +49 402396-3661
Germany
Email :vergabestelle@dak.de
URL :www.dak.de

Tender Details

Object of the contract
Pharmaceutical products

Description: Contract notice: Pharmaceutical products

Authority Type: Body governed by public law
Contact Nature: Supplies
Procedure: Open procedure
Document: Contract notice
Regulation: European Union
Award criteria: Lowest price
CPV code: 33600000, 33600000
CPV Description: Pharmaceutical products.

Completion of a non-exclusive discount agreement pursuant to - 130a Abs. 8 SGB V to the active substance Caspofungin, ATC J02AX04, for the period 01.09.2017 31.08.2019 Allows health insurance companies and pharmaceutical companies to carry out framework agreements on the drugs to be handed over to the statutory health insurance fundsTtel to close. With regard to the statutory provisions governing the award of public contracts, a regular process of drug-related, so-called tendering procedure takes place according to the regulations of the fourth part of the GWB by the DAK-G. For medicinal products to be designated by the tenderer in Annex 2 to the contract to the active substance caspofungin, ATC J02AX04, beabsicThe DAK-G undertakes to conclude drug discounts contracts with the most possible pharmaceutical companies by the time of the entry into force of new drug discounts. A discount agreement within the scope of the admission model for the above- Active substance enters into force for the first time on 1.9.2017 and ends on 31.8.2019. It ends automatically with the entry into force of the exclusive contractAK-G assumes that this procedure does not come within the scope of the antitrust law because of the lack of a selection decision and the non-discriminatory accessibility of all pharmaceutical companies. It shall terminate automatically, with the entry into force of the exclusive agreement to Caspofungin, ATC J02AX04, as a result of a public procurement procedureThe regulations of the fourth part of the GWB with one or more contract partners. In order to meet the diversity of the potential contract partners within the framework of the licensing model, each pharmaceutical company is allowed to conclude a framework contract at any time and under the same conditions during the contract period. The contract documents required for this purpose are availableThe online portal www.dtvp.de/center under the I.3., The complete and timely transmission of the following proofs / declarations / attachments (available for download under the conditions described under I. 3) to the followingEnded contact person at the DAK-G:

1. Letter of Offer

2nd Current proof of entry in the professional or commercial register (see III.1.1.)

3. Declaration by the company (Annex A1) that none of the exclusion criteria is in accordance with -- 123, 124 GWB (see III.1.1.). A declaration that the medicinal products for which the interested party has a contract under-Of this procedure, there is an authorization under the law on medicinal products, and the tenderer is entitled to sell (Annex A2) (see III.1.1. Declaration by the company that the statutory provisions on the minimum wage and tariff refusal are respected and complied with (Annex A3) (see III.1.1.). Recognition of the contractual provisions of DAK-GesundIn particular also the specified discounts by the signing of the contract stamped with a company stamp (2 times in the original) by the interested party at the designated place. The completed enclosures 1 and 2 to the contract (2-fold in the original). The interested party has the drugs to the above mentioned. Substance, which shall be the object of the contract. Effective Pra(DAK Health),

Henri Affinass (0032 50),

Nagelsweg 27-31,

20097.

The documents must be submitted by post to: Hamburg.

In addition, the attachment 2 as an Exceldatei at the same time send to the mail address am_rabattvertraege@dak.de. Contracts within the scope of this model and to the above. Active substance are effective for the first time-Ending on 1 September 2017 and ending on 31.8.2019. Interested parties wishing to become contractors on this date have the documents to be submitted by the 5th of the previous month, Position. This is due to the timely access to DAK health. Later accessions are possible at any time. For the duration of the contract to the 1st or 15th of the followingMonths, the above- Documents, irrespective of the desired accession, of the DAK health up to the 5th of the previous month. This also applies to the timely access to the DAK-G. Example: The bidding requested by the bidder is to be made on 15.7.20xx (follow-up), the documents must be submitted by 5.6.20xx (previous month)Is made using the form for open procedures. As already made clear, this is not such a notice had to be used for technical reasons, since there is no suitable form for approval procedure. Current proof of entry in the professional or trade register (not more than 6 months in case of dispatch) nIn accordance with the legislation of the country in which the undertaking is established, Eg current commercial register extract; Copy is sufficient.

2. Declaration by the company that none of the exclusion criteria is in accordance with -- 123, 124 GWB. To this end, the A1 is to be signed, to be stamped with the company stamp and to be submitted in the original. Declare that for thejFor which the interested party wishes to conclude a contract under this procedure, is subject to authorization under the law on medicinal products and that the tenderer is entitled to sell it at the start of the contract (Annex A2) (see III.1.1.). Declaration of the company that the statutory provisions on the minimum wage and the tariff refusal are observed and complied with (Annex A3). ThereThe DAK-Gesundheit has published a so-called prequalification procedure for pharmaceutical companies for the simplified participation in future drug discounts (EU-announcement 2015 / S 105- 190319 of June 3, 2015). If the-(Proof of the entry in the professional or trade register, the company's own declaration that none of the exclusion criteria in accordance with -- 123, 124 GWB is available) must be provided by the DAK-Gesundheit in good time before submission of the documents, Safety certification of the legal craneWith the reference and annexation of the prequalification certificate. Annex A2 is to be added in all cases. The DAK health pre-qualification certificate also serves as a proof for open-house DAK health procedures, regardless of the value of the contract.

It is self-declaration that the medicinal products for which the interested party is entitled, N agreement within the framework of this procedure, there is an authorization under the drug law and that the tenderer is entitled to sell at the start of the contract. For this purpose, the attachment A2 has to be signed, stamped with the company stamp and submitted in the original. DAK Health has a so-called pre-qualification procedure for pharmaceuticals through the European publicity platform(Published in the EU notice 2015 / S 105-190319 of 03.06.2015). If the bidder has received an effective pre-qualification notice from the DAK health in good time before submission of the dossier, he needs the company-specific suitability proofs (proof of the entry in the BerTrade or commercial register, the company's own declaration that none of the exclusion criteria pursuant to Art. -- 123, 124 GWB, safety certificate of the statutory health insurance fund) with copy and annex of the prequalification certificate in copy no more. Annex A2 is to be added in all cases. The pre-qualification notice for the DAK health is corresponding to aUch as proof of open-house procedures of DAK health.

The contract documents can also be sent by e-mail to the address given in I.1. Must be requested. The tender documents will then be sent by e-mail. Questions and notes on the tender documents are published electronically (via bidder communication via the award portal www.dtvp.de)Or in individual cases by e-mail or in writing (by fax or letter) to the persons mentioned under I.1. Contact point. They are to be formulated in German. Responses will be made available in anonymous form to all contractors who requested the registration documents by means of a registration. In doing so, He offers bidder communication via the allocation portal www.dtvp.de. Companies who have downloaded the tender documents without registration must, on their own responsibility, pursue the further communication and, if necessary, This publication is not a public procurement contractWithin the meaning of the Public Procurement Coordination Directive 2014/24 / EU of the European Parliament and of the Council, In order to ensure the widest degree of transparency for the intended

contract conclusion, the supplement is published in the Official Journal of the European Union. In the absence of a corresponding publication form, the order will be acknowledgedTo be used. The resulting conceptual specifications, such as, for example, the procedure description "Open procedure", are solely due to the use of this publication form and to the publishing platform ver.

Announcement ID: CXP4YM5YE7G.


Internet address (URL): www.dak.de
Directive: Classical Directive (2014/24/EU)

Documents

 Tender Notice